|Event Date/Time: Oct 06, 2011||End Date/Time: Oct 07, 2011|
6th - 7th October, Rome, Italy
How successful are you in managing the increasingly complex Market Access environment? What is the role of economic evaluation with regards to the availability of new innovative cancer drugs?
HTA agencies, Pharma industry, Academics, Doctors and Patients will be a part of our conference in Rome. Come as well and discover new reimbursement schemes, price cuts, organisational re-design during the presentations of experts from industry who already implemented some of these changes.
Head of Market Access & Economic Affairs - Pfizer, Italy
Head Pricing, Health Economics, & Outcome Research Europe - Novartis Oncology, Spain
Senior Director Reimbursement - Cephalon, USA
Senior Lecturer in International Health Policy - The London School of Economics and Political Science, UK
Head of Recommendations Division, Presidentâ€˜s Office - AHTAPol, Poland
Office for Pharmaceutical Policy - AIFA, Italy
Reasons to attend:
Unlock Oncology Market Access across Europe â€“ how to deal with the increasing complexity and uncertainty in current pricing & reimbursement environment
Develop effective market access strategy & succeed in pricing negotiations
Find a balance between early patient access to new cancer drugs & the need for benefit/risk data
Reveal cost-effectiveness measures & the impact on the industry â€“ is the innovation rewarded correctly?
Make market access an integral part of the company & incorporate market access into the entire drugâ€™s life cycle â€“ what is the new market access model?
Discover the role of HTAs â€“ the importance of early dialogue with HTA agencies
Understand funding of new cancer drugs in the future â€“ healthcare & hospital budgets challenges â€“ towards more effective resources allocation
Explore the concept of risk-sharing
For further information visit: http://pharma.flemingeurope.com/clinical-trials-in-oncology/ or contact Martina Izak on email@example.com or +421 257 272 137.